Melioidosis vaccines

References

• Dance DA. Melioidosis: the tip of the iceberg? Clin. Microbial. Rev 4(1), 52–60 (1991).
   Google Scholar
• Currie BJ, Fisher DA, Howerd DM et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. 31(4), 981–986 (2000).
   Google Scholar
• Abbink FC, Orendi JM, de Beaufort AJ. Mother-to-child transmission of Burlcholderia pseudomallet N Enj Med 344(15), 1171–1172 (2001).
   Google Scholar
• McCormick JB, Sexton DJ, McMurray JG, Carey E, Hayes P, Feldman RA. Human-to-human transmission of Pseudomonas pseudomallet Ann. Intern. Med. 83(4), 512–513 (1975).
   Google Scholar
• Gutner LB, Fisher MW Chronic melioidosis: discussion, case report and special studies. Ann. Intern. Med. 28,1157–1169 (1947).
   Google Scholar
• Chodimella U, Hoppes WL, Whalen S, Ognibene AJ, Rutecki GW. Septicemia and suppuration in a Vietnam veteran. Hasp. Pract (Off. Ed.) 32(5), 219–221 (1997).
   Google Scholar
• Currie BJ, Fisher DA, Howard DM et al. The epidemiology of melioidosis in Australia and Papua New Guinea. Acta Pop. 74(2-3), 121–127 (2000).
   Google Scholar
• Leelarasamee A, Bovomkitti S. Melioidosis: review and update. Rev Infect. Dir. 11(3), 413–425 (1989).
   Google Scholar
• Guard RW, Khafagi FA, Brigden MC, Ashdown LR. Melioidosis in Far North Queensland. A clinical and epidemiological review of twenty cases. Am. j Pop. Med. Hyg: 33(3), 467–473 (1984).
   Google Scholar
• White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 2(8665), 697–701 (1989).
   Google Scholar
• Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob. Agents Chemother: 36(1), 158–162 (1992).
   Google Scholar
• Suputtamongkol Y, Rajchanuwong A, Chaowagul W et al Ceftazidime vs. amoxicilliniclavulanate in the treatment of severe melioidosis. Clin. Infect. Dir. 19(5), 846–853 (1994).
   Google Scholar
• Simpson AJ, Suputtamongkol Y, Smith MD et al Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin. Infect. Dis. 29(2), 381–387 (1999).
   Google Scholar
• Apisarnthanarak A, Little JR. The role of cefoperazone—sulbactam for treatment of severe melioidosis. Clin. Infect. Dir. 34(5), 721–723 (2002).
   Google Scholar
• Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin. Infect. Dis. 33(1), 29–34 (2001).
   Google Scholar
• Chaowagul W Suputtamongkol Y, Dance DanceD, Rajchanuvong A, Pattara-arechachai White, J. NJ. Relapse in melioidosis: incidence and risk factors. J. Infect. Dir. 168(5), 1181–1185 (1993).
   Google Scholar
• Chetchotisakd P, Chaowagul W, Mootsikapun P, Budhsarawong D, Thinkamrop B. Maintenance therapy of melioidosis with ciprofloxacin plus azithromycin compared with cotrimoxazole plus doxycycline. Am j Trop. Med. Hyg. 64(1–2), 24–27 (2001).
   Google Scholar
• Stephens DP, Fisher DA, Currie BJ. An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern. Med 32(4), 143–148 (2002).
   Google Scholar
• Santanirand P, Harley VS, Dance DA, Drasar BS, Bancroft GJ. Obligatory role of gamma interferon for host survival in a murine model of infection with Burkholderia pseudomallei. Infect. Immun. 67(7), 3593–3600 (1999).
   Google Scholar
• Pruksachartvuthi S, Aswapokee N, Thankemgpol K. Survival of Pseudomonas pseudomallei in human phagocytes. j Med. Nlicrobiol 31(2), 109–114 (1990).
   Google Scholar
• Jones AL, Beveridge TJ, Woods DE. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 64(3), 782–790 (1996).
   Google Scholar
• Harley VS, Dance DA, Tovey G, McCrossan MV, Drasar BS. An ultrastructural study of the phagocytosis of Burkholderia pseudomallel Nlitrobios. 94(377), 35–45 (1998).
   Google Scholar
• Nigg C et al. Toxin produced by Malleomyces pseudomallei. Proc. Soc. Exp. Biol. Med. 89(1), 17–20 (1955).
   Google Scholar
• Hecldy RJ, Nigg C. Toxins of Pseudomonas pseudomallei. j Bacterial. 76(4), 427–436 (1958).
   Google Scholar
• Lee MA, Liu Y. Sequencing and characterization of a novel serine metalloprotease from Burkholderia pseudomallei. FEMS Mcrobiol Lett. 192(1), 67–72 (2000).
   Google Scholar
• Percheron G, Thibault F, Paucod J, Vidal D. Burkholderia pseudomallei requires Zn2+ for optimal exoprotease production in chemically defined media. AppL Environ. Nlicrobiol 61(8), 3151–3153 (1995).
   Google Scholar
• Sexton MM, Jones AL, Chaowagul AW, Woods DE. Purification and characterization of a protease from fieudomonas pseudomallei. Can. .1. Mcrobiol 40(11), 903–910 (1994).
   Google Scholar
• Korbsrisate S, Suwanasai N, Leelaporn A, Ezaki T, Karamura Y, Sarasombath S. Cloning and characterization of a nonhemolytic phospholipase C gene from Burkholderia pseudomallei. j Clin. Mcrobiol 37(11), 3742–3745 (1999).
   Google Scholar
• Ashdown LR, Koehler JM. Production of hemolysin and other extracellular enzymes by clinical isolates of lieudomonas pseudomallei. j Clin. Nfirmbiol. 28(10), 2331–2334 (1990).
   Google Scholar
• DeShazer D, Brett PJ, Burtnick MN, Woods DE. Molecular characterization of genetic loci required for secretion of exoproducts in Burkholderia pseudomallei. Bacterial. 181(15), 4661–4664 (1999).
   Google Scholar
• Attree 0, Attree I. A second Type III secretion system in Burkholderia pseudomallet. who is the real culprit? Mcrobiology147\(Pt 12), 3197–3199 (2001).
   Google Scholar
• Winstanley C, Hales BA, Hart CA. Evidence for the presence in Burkholderia pseudomallei of a Type III secretion system-associated gene cluster. j Med. Illicmbiol. 48(7), 649–656 (1999).
   Google Scholar
• Rainbow L, Hart CA, Winstanley C. Distribution of Type III secretion gene clusters in Burkholderia pseudomallei, B. thailandensis and B. mallet .1. Med. Mcrobiol 51(5), 374–384 (2002).
   Google Scholar
• Galan JE. Salmonella interactions with host cells: Type III secretion at work. Ann. Rev Cell Dev. Biol. 17, 53–86 (2001).
   PubMed Web of Science ®Google Scholar
• Charuchaimontri C, Suputtamongkol Y, Nilakul C et al Antilipopolysaccharide an antibody protective against fatal melioidosis. Clin. Infect Ds 29(4), 813–818 (1999).
   Google Scholar
• DeShazer D, Brett PJ, Carlyon R,Woods DE. Mutagenesis of Burkholderia pseudomallei with Tn5-0T182: isolation of motility mutants and molecular characterization of the flagellin structural gene. Bacterial 179(7), 2116 —2125 (1997).
   Google Scholar
• Perry MB, McLean LL, Schollaardt T, Bryan LE, Ho M. Structural characterization of the lipopolysaccharide 0 antigens of Burkholderia pseudomallet Infect. Immun. 63(9), 3348–3352 (1995).
   Google Scholar
• Masoud H, Schollaardt T, Perry MB. Characterization of the capsular polysaccharide of Burkholder-1a (Pseuclomona pseudomallei 304b. J Bacterial 179(18), 5663–5669 (1997).
   Google Scholar
• Bryan LE et al Passive protection of diabetic rats with anfisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei. n.j Infect. Dis 5(4), 170–178 (1994).
   Google Scholar
• Brett PJ, Mah DC, Woods DE. Isolation and characterization of Pseudomonas pseudomalleiflagellin proteins. Infect. Immun. 62(5), 1914–1919 (1994).
   Google Scholar
• Ulett GC, Ketheesan N, Hirst RG. Cytokine gene expression in innately susceptible BALB/ c mice and relatively resistant C57B1/6 mice during infection with virulent Burkholderia pseudomallei Infect. hirmun 68(4), 2034-2042 (2000).
   Google Scholar
• Brett PJ, Woods DE. Structural and immunological characterization of Burkholderia pseudomallei 0 -polysaccharide—flagellin protein conjugates. Infect. Immun. 64(7), 2824 —2828 (1996).
   Google Scholar
• DeShazer D, Waag DM, Fritz DL, Woods DE. Identification of a Burkholderia mallei polysaccharide gene cluster by subtractive hybridization and demonstration that the encoded capsule is an essential virulence determinant. Mcrob. Pathog. 30(5), 253–269 (2001).
   Google Scholar
• Burtnick MN, Brett PJ, Woods DE. Molecular and physical characterization of Burkholderia mallei 0 antigens. J. Bacterial. 184(3), 849–852 (2002).
   Google Scholar
• Reckseidler SL, DeShazer D, Sokol PA, Woods DE. Detection of bacterial virulence genes by subtractive hybridization: identification of capsular polysaccharide of Burkholderia pseudomallei as a major virulence determinant. Infect. Immun. 69(1), 34–44 (2001).
   PubMed Web of Science ®Google Scholar
• Cryz SJ Jr, Furer E, Sadoff JC et al. Use of lieudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins. Rev Infect. Dis. 9 (Suppl. 5), S644-649 (1987).
   Google Scholar
• Leung BPS. A DNA vaccine for melioidosis. University of Calgary Masters of Science thesis (2000).
   Google Scholar
• Atkins T, Proir R, Mack K et al Characterisation of an acapsular mutant of Burkholderia pseudomallei identified by signature tagged mutagenesis. J Med. Mcrobiol 51(7), 539–547 (2002).
   Google Scholar
• Ulett GC, Ketheesan N, Clair TVV, McElnea CL, Barnes JL, Hirst RG. Analogous cytokine responses to Burkholderia pseudomallei strains contrasting in virulence correlate with partial cross-protection in immunized mice. Infect. Immun. 70(7), 3953–3958 (2002).
   Google Scholar
• Atkins T, Proir R, Mack K et al. A mutant of Burkholderia pseudomallei, auxotrophic in the branched chain amino acid biosynthetic pathway, is attenuated and protective in a murine model of melioidosis. Infect. Immun. 70(9), 5290–5294 (2002).
   PubMed Web of Science ®Google Scholar
• Ilyukhin VI et al. [Burkholderia thailandensis biological properties, identification and taxonomy]. Mal Gen. Virusol (1), 7–11 (2002).
   Google Scholar
• Manzeniuk IN, Galina EA, Dorokhin VV, Khalachev II, Borzenkov VN, Svetoch EA. [Burkholderia mallei and Burkholderia pseudomallei. Study of immuno- and pathogenesis of glanders and melioidosis. Heterologous vaccines]. Antibiot. Khimioter. 44(6), 21–26 (1999).
   Google Scholar
• Choy JL, Mayo M, Janmaat A, Currie BJ. Animal melioidosis in Australia. Acta Trop. 74(2-3), 153–158 (2000).
   Google Scholar